Dr. Schiffman received his B.S. degree with High Honors in biology from Hobart College in 1976. He then moved to Chicago where he studied biochemistry at the University of Illinois, Chicago Circle. He attended Rush Medical College where he received his M.D. degree in 1982 and was elected to the Alpha Omega Alpha Medical Honor Society. He completed his Internal Medicine internship and residency at the University of California, Irvine.
Melissa Conrad Stöppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stöppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology.
Treatment to prevent TB in a single person aims to kill walled-up germs that are doing no damage right now but could break out years from now and become active.
If you should be treated to prevent sickness, your doctor usually prescribes a daily dose of isoniazid (also called INH), an inexpensive TB medicine.
You will take INH for up to a year, with periodic checkups to make sure you
are taking it as prescribed and that it is not causing undesirable side effects.
In some cases, intolerance or allergic response can mandate an alternative
treatment that may go on for 18 months.
Treatment also can stop the spread of TB in large populations.
The tuberculosis vaccine, known as bacille Calmette-Guérin (BCG) may prevent the spread of tuberculosis and tuberculous meningitis in children, but the vaccine does not necessarily protect against pulmonary tuberculosis. It can, however, result in a false-positive tuberculin skin test that in many cases can be differentiated by the use of the QuantiFERON-TB Gold test mentioned above.
Health officials generally recommend the vaccine in countries or communities where the rate of new infection is greater than 1% per year. BCG is not generally recommended for use in the United States because there is a very low risk of tuberculosis infection. It may be considered for very select patients at high risk for tuberculosis and who meet special criteria.